Disclaimer
The treatment offered is part of an investigational international pilot study. This experimental treatment is not FDA approved.
Revolutionize the treatment of metastatic and advanced-stage cancers through the pioneering Targeted Osmotic Lysis (TOL) therapy
We envision a future where cancer patients have access to a safe, effective, and well-tolerated treatment option that can significantly improve their quality of life and provide hope for a better outcome.
The TOL pilot study aims to validate this innovative approach in clinical settings and pave the way for its broader acceptance and implementation.
Our vision is to establish TOL as a viable tool in the fight against cancer by offering a targeted and minimally invasive solution for patients who have exhausted other options or are seeking a complementary therapy.
Under an official Ethics Board Approval, the pilot study has been reviewed and approved. The Ethics Board represents an independent committee that protects the rights and welfare of human research subjects.
Targeted Osmotic Lysis (TOL) is a Potentially Groundbreaking Cancer Treatment
Harnesses the unique biological properties of cancer cells to selectively target and destroy them. Unlike conventional therapies that indiscriminately attack both cancerous and healthy cells, TOL exploits the overexpression of voltage-gated sodium channels (VGSCs) and sodium-potassium pumps in cancer cells.
By activating the overexpressed VGSCs and simultaneously blocking the Na+, K+-ATPase pumps with a cardiac glycoside
TOL induces an influx of sodium ions and water into the cancer cells, causing them to swell and ultimately burst due to the increased osmotic pressure. Remarkably, this process spares normal cells, which do not exhibit the same level of VGSC and pump overexpression.
The TOL pilot study is built upon promising results from preclinical studies
Early clinical results from previous pilot studies (companion animal trials, and preliminary human case reports) have been published. In addition, two patients with Stage 4 metastatic pancreatic carcinoma were treated with TOL and had reduced tumor size based on post-treatment imaging.
TOL has also demonstrated efficacy in other cancers, such as malignant melanoma and cutaneous squamous cell carcinoma, with complete resolution of primary lesions in case reports (see Case Studies section)
In preclinical studies we have also seen potential benefit in astrocytoma, glioblastoma, diffuse midline glioma, advanced pancreatic carcinoma, advanced cervical carcinoma, advanced signet cell adenocarcinoma, and others. In a review of patient outcomes, many patients reported increased energy, better appetite, sleep, and strength post-treatment, with no adverse effects noted.
Learn More About Our Novel Cancer Treatment
TOL is a groundbreaking cancer treatment that selectively targets and destroys cancer cells while sparing healthy cells. Learn more about our innovative approach and how it can benefit you or a loved one.
